Gut microbes as biomarkers of ICI response - sharpening the focus

doi:10.1038/s41571-022-00634-0

Comment

. 2022 Aug;19(8):495-496.

doi: 10.1038/s41571-022-00634-0.

Gut microbes as biomarkers of ICI response - sharpening the focus

Neal Bhutiani¹, Jennifer A Wargo^{2

3}

Affiliations

¹ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
³ Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.

PMID: 35449306
DOI: 10.1038/s41571-022-00634-0

Comment

Gut microbes as biomarkers of ICI response - sharpening the focus

Neal Bhutiani et al. Nat Rev Clin Oncol. 2022 Aug.

. 2022 Aug;19(8):495-496.

doi: 10.1038/s41571-022-00634-0.

Authors

Neal Bhutiani¹, Jennifer A Wargo^{2

3}

Affiliations

¹ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
³ Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.

PMID: 35449306
DOI: 10.1038/s41571-022-00634-0

No abstract available

PubMed Disclaimer

Comment on

Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Leeming ER, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Vijay A, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Bataille V, Hospers GAP, Spector TD, Weersma RK, Segata N. Lee KA, et al. Nat Med. 2022 Mar;28(3):535-544. doi: 10.1038/s41591-022-01695-5. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228751 Free PMC article.
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.
McCulloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, Balaji AK, Vetizou M, Prescott SM, Fernandes MR, Costa RGF, Yuan W, Salcedo R, Bahadiroglu E, Roy S, DeBlasio RN, Morrison RM, Chauvin JM, Ding Q, Zidi B, Lowin A, Chakka S, Gao W, Pagliano O, Ernst SJ, Rose A, Newman NK, Morgun A, Zarour HM, Trinchieri G, Dzutsev AK. McCulloch JA, et al. Nat Med. 2022 Mar;28(3):545-556. doi: 10.1038/s41591-022-01698-2. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228752 Free PMC article.

Cited by

Current approaches in glioblastoma multiforme immunotherapy.
Aghajani M, Jalilzadeh N, Aghebati-Maleki A, Yari A, Tabnak P, Mardi A, Saeedi H, Aghebati-Maleki L, Baradaran B. Aghajani M, et al. Clin Transl Oncol. 2024 Jul;26(7):1584-1612. doi: 10.1007/s12094-024-03395-7. Epub 2024 Mar 21. Clin Transl Oncol. 2024. PMID: 38512448 Review.
Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.
Talebi F, Gregucci F, Ahmed J, Ben Chetrit N, D Brown B, Chan TA, Chand D, Constanzo J, Demaria S, I Gabrilovich D, Golden E, Godkin A, Guha C, P Gupta G, Hasan A, G Herrera F, Kaufman H, Li D, A Melcher A, McDonald S, Merghoub T, Monjazeb AM, Paris S, Pitroda S, Sadanandam A, Schaue D, Santambrogio L, Szapary P, Sage J, W Welsh J, Wilkins A, H Young K, Wennerberg E, Zitvogel L, Galluzzi L, Deutsch E, C Formenti S. Talebi F, et al. Oncoimmunology. 2025 Dec;14(1):2507856. doi: 10.1080/2162402X.2025.2507856. Epub 2025 May 22. Oncoimmunology. 2025. PMID: 40401900 Free PMC article. Review.
Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions.
Zhang C, Zhang C, Wang K, Wang H. Zhang C, et al. J Transl Med. 2023 Jul 14;21(1):468. doi: 10.1186/s12967-023-04338-6. J Transl Med. 2023. PMID: 37452395 Free PMC article. Review.
An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome.
Jiang S, Ma W, Ma C, Zhang Z, Zhang W, Zhang J. Jiang S, et al. Gut Microbes. 2024 Jan-Dec;16(1):2341717. doi: 10.1080/19490976.2024.2341717. Epub 2024 May 8. Gut Microbes. 2024. PMID: 38717360 Free PMC article. Review.
Therapeutic potential of Clostridium butyricum anticancer effects in colorectal cancer.
Xu H, Luo H, Zhang J, Li K, Lee MH. Xu H, et al. Gut Microbes. 2023 Jan-Dec;15(1):2186114. doi: 10.1080/19490976.2023.2186114. Gut Microbes. 2023. PMID: 36941257 Free PMC article.

See all "Cited by" articles

References

1. Andrews, M. C. et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat. Med. 27, 1432–1441 (2021). - DOI
1. Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018). - DOI
1. Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018). - DOI
1. Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021). - DOI
1. Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021). - DOI

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group

[1] Andrews, M. C. et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat. Med. 27, 1432–1441 (2021). - DOI

[2] Andrews, M. C. et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat. Med. 27, 1432–1441 (2021). - DOI

[3] Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018). - DOI

[4] Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018). - DOI

[5] Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018). - DOI

[6] Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018). - DOI

[7] Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021). - DOI

[8] Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021). - DOI

[9] Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021). - DOI

[10] Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021). - DOI

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Gut microbes as biomarkers of ICI response - sharpening the focus

Affiliations

Gut microbes as biomarkers of ICI response - sharpening the focus

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources